PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis-Reference-Cited by-同舟云学术

PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis

Published:2014-11 Issue:14 Volume:15 Page:1763-1769
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Julià Antonio¹,Rodríguez Jesús²,Fernández-Sueiro José Luis³,Gratacós Jordi⁴,Queiró Rubén⁵,Montilla Carlos⁶,Torre-Alonso Juan Carlos⁷,Pérez-Venegas José Javier⁸,Manrique-Arija Sara⁹,Muñoz-Fernández Santiago¹⁰,González Carlos¹¹,Roig Daniel¹²,Zarco Pedro¹³,Erra Alba¹⁴,Castañeda Santos¹⁵,García Alicia¹⁶,Salvador Georgina¹⁷,Díaz-Torne César¹⁸,Blanco Ricardo¹⁹,Domínguez Alfredo Willisch²⁰,Mosquera José Antonio²¹,Vela Paloma²²,Tornero Jesús²³,Sánchez-Fernández Simón²⁴,Corominas Héctor¹²,Ramírez Julio²⁵,Ávila Gabriela¹,Alonso Arnald¹,Tortosa Raül¹,López-Lasanta María¹,Cañete Juan D²⁵,Marsal Sara¹

Affiliation:

1. Rheumatology Research Group, Vall d‘Hebron Research Institute, Barcelona, 08035, Spain

2. Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, 08907, Spain

3. Rheumatology Department, Complejo Hospitalario Juan Canalejo, A Coruña, 15006, Spain

4. Rheumatology Department, Hospital Parc Taulí, Sabadell, Barcelona, 08208, Spain

5. Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, 33006, Spain

6. Rheumatology Department, Hospital Virgen de la Vega, Salamanca, 37007, Spain

7. Rheumatology Department, Hospital Monte Naranco, Oviedo, 33012, Spain

8. Rheumatology Department, Hospital de Jerez de la Frontera, Cádiz, 11407, Spain

9. Rheumatology Department, Hospital Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Universidad de Málaga, 29009, Spain

10. Rheumatology Department, Hospital Universitario Infanta Sofía, Madrid, 28702, Spain

11. Rheumatology Department, Hospital Universitario Gregorio Marañón, Madrid, 28009, Spain

12. Rheumatology Service, Hospital Moisès Broggi, Barcelona, Spain

13. Rheumatology Department, Hospital Universitario Fundación Alcorcón, Madrid, 28922, Spain

14. Rheumatology Department, Hospital Sant Rafael, Barcelona, 08035, Spain

15. Rheumatology Department, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, 28006, Spain

16. Rheumatology Department, Centro de Salud Virgen de los Reyes, Sevilla, Spain

17. Rheumatology Department, Hospital Mútua de Terrassa, Terrassa, Spain

18. Rheumatology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

19. Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

20. Rheumatology Department, Complexo Hospitalario de Ourense, Ourense, Spain

21. Rheumatology Department, Complejo Hospitalario Hospital Provincial de Pontevedra, Pontevedra, Spain

22. Rheumatology Department, Hospital General Universitario de Alicante, Alicante, Spain

23. Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain

24. Rheumatology Department, Hospital La Mancha Centro, Alcázar de San Juan, Spain

25. Rheumatology Department, Hospital Clínic de Barcelona and IDIBAPS, Barcelona, 08036, Spain

Abstract

Aim: Variation at PDE3A-SLCO1C1 locus has been recently associated with the response to anti-TNF therapy in rheumatoid arthritis. We undertook the present study to determine whether PDE3A-SLCO1C1 is also associated with the response to anti-TNF therapy in psoriatic arthritis. Patients & methods: Genomic DNA was obtained from 81 psoriatic arthritis patients that had been treated with anti-TNF therapy. PDE3A-SLCO1C1 SNP rs3794271 was genotyped using Taqman realt-time PCR. The clinical response to anti-TNF therapy was measured as the change from baseline in the level of disease activity according to the DAS28 score. Results: A significant association between rs3794271 and anti-TNF response in psoriatic arthritis was found (beta = -0.71; p = 0.0036). Conclusion: PDE3A-SLCO1C1 locus is also associated with response to anti-TNF therapy in psoriatic arthritis. Original submitted 12 May 2014; Revision submitted 18 August 2014

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.14.125

Reference31 articles.

1. Future Trends in Research in Psoriatic Arthritis

2. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study

3. The prevalence of psoriatic arthritis in people with psoriasis

4. Risk variants for psoriasis vulgaris in a large case–control collection and association with clinical subphenotypes

5. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MIF Variant rs755622 Is Associated with Severe Crohn’s Disease and Better Response to Anti-TNF Adalimumab Therapy;Genes;2023-02-09

2. Unraveling the complexities of psoriatic arthritis by the use of -Omics and their relevance for clinical care;Autoimmunity Reviews;2021-11

3. The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review;Frontiers in Genetics;2021-07-20

4. Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis;Journal of Personalized Medicine;2020-12-29

5. Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine;Expert Review of Precision Medicine and Drug Development;2020-01-02